News

NEJM stands by its criticism of Vioxx study

BMJ 2006; 332 doi: 10.1136/bmj.332.7540.505-a (Published 2 March 2006)
Cite this as: BMJ 2006;332:505.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Janice Hopkins Tanne
  1. New York

    The New England Journal of Medicine last week reaffirmed the expression of concern that it made last December, about the omission of three heart attacks from a study of rofecoxib (Vioxx) published in 2000. The online editorial was published on 22 February 2006 (http://content.nejm.org, doi: 10.1056/NEJMe068054).

    The journal also published responses from 11 authors of the study who are not employed by Merck, the drug's manufacturer, and from two authors who are (doi: 10.1056/NEJMc066096).

    The controversy concerns the VIGOR (Vioxx gastrointestinal outcomes research) study, which compared upper gastrointestinal toxicity of rofecoxib with naproxen and was published in the journal in 2000 (New England Journal of Medicine 2000;343: 1520-8).

    Last year, the journal editors reviewed electronic documents relating to the study when the journal's executive …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular